Side effects in the LIBTAYO study

What are the possible side effects of LIBTAYO?

LIBTAYO can cause serious side effects. Click here to review “What is the most important safety information I should know about LIBTAYO?” The most common side effects of LIBTAYO include tiredness, muscle or bone pain, rash, diarrhea, and low levels of red blood cells (anemia). These are not all the possible side effects of LIBTAYO. Call your doctor for medical advice about side effects.

In the LIBTAYO clinical trial which included patients with advanced BCC previously treated with an HHI, the most common side effects were:

  • 69 out of 138 patients (50%)
    experienced tiredness

  • 50 out of 138 patients (36%)
    experienced muscle or bone pain

  • 46 out of 138 patients (33%)
    experienced diarrhea

  • 41 out of 138 patients (30%)
    experienced having a rash

  • 30 out of 138 patients (22%)
    experienced infection of the nose, throat, and/or airways

  • 26 out of 138 patients (19%)
    experienced itching

  • 25 out of 138 patients (18%)
    experienced hemorrhaging (loss of blood from damaged blood vessels)

  • 23 out of 138 patients (17%)
    experienced high blood pressure

  • 19 out of 138 patients (14%)
    experienced a loss of appetite

  • 19 out of 138 patients (14%)
    experienced anemia
    (low red blood cell count)

  • 19 out of 138 patients (14%)
    experienced shortness of breath

  • 19 out of 138 patients (14%)
    experienced acute kidney injury (sudden decline in kidney functions)

  • 18 out of 138 patients (13%)
    experienced nausea

  • 18 out of 138 patients (13%)
    experienced a UTI
    (urinary tract infection)

  • 18 out of 138 patients (13%)
    experienced headaches

  • 17 out of 138 patients (12%)
    experienced pain in the stomach area (abdomen)

  • 17 out of 138 patients (12%)
    experienced constipation

  • 17 out of 138 patients (12%)
    experienced dizziness

  • 17 out of 138 patients (12%)
    experienced hypothyroidism (underactive thyroid)

  • 15 out of 138 patients (11%)
    experienced numbness, pain, tingling, or burning in the hands or feet

  • 14 out of 138 patients (10%)
    experienced swelling

  • 14 out of 138 patients (10%)
    experienced liver function test abnormalities

Review examples of patient
responses to LIBTAYO
in clinical trials.

See the responses